Olatz Etxániz

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

Xavier García del Muro, Begoña P. Valderrama, Ana Medina et al. · Journal of Clinical Oncology · 2021 · 34 citations

Medicine, Oncology, Urology +17

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas

Olatz Etxániz, Cristina Carrato, Itziar de Aguirre et al. · Journal of Neuro-Oncology · 2017 · 24 citations

Medicine, Molecular Genetics, Oncology +17

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation

Laia Capdevila, Sara Cros, José Luis Ramírez et al. · Journal of Neuro-Oncology · 2014 · 23 citations

Medicine, Oncology, Pharmacology +17

The influence of treatment sequence in the prognostic value of <i>TMPRSS2‐ERG</i> as biomarker of taxane resistance in castration‐resistant prostate cancer

Mercedes Marín‐Aguilera, Òscar Reig, Maria Milà‐Guasch et al. · International Journal of Cancer · 2019 · 21 citations

Medicine, Oncology, Pharmacology +17

SEOM—GECOD clinical guideline for unknown primary cancer (2021)

Ferrán Losa, Isaura Fernández, Olatz Etxániz et al. · Clinical & Translational Oncology · 2022 · 20 citations · Full text

Medicine, Molecular Medicine, Oncology +17